Options Movement At Alnylam Pharmaceuticals: Yvonne Greenstreet Exercises Worth $1.72M

The latest update on Tuesday morning shows Alnylam Pharmaceuticals shares up by 3.84%, trading at $472.0. At this price, ...
Oregonian

Dear Doctor: High lipoprotein(a) levels alone aren’t enough to consider patient high risk of heart disease

DEAR DR. ROACH: I’m a healthy 50-year-old woman. I asked my doctor to test me for Lipoprotein(a) after reading about it. My level was high, at 41 mg/dL. My doctor told me that it didn’t need to be ...
BioSpace

FDA Unwraps ‘Plausible Mechanism Pathway’ for Personalized Therapies

The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed. Individualized therapies ...
FierceBiotech

UPDATED: Prasad, Makary unveil new FDA path for accelerating custom gene editing therapies

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies ...